APA (7th ed.) Citation

Comi, G., Cook, S., Rammohan, K., Soelberg Sorensen, P., Vermersch, P., Adeniji, A. K., . . . Giovannoni, G. (2018). Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: The CLARITY Extension study. Therapeutic advances in neurological disorders, 11, 1756285617753365. https://doi.org/10.1177/1756285617753365

Chicago Style (17th ed.) Citation

Comi, Giancarlo, Stuart Cook, Kottil Rammohan, Per Soelberg Sorensen, Patrick Vermersch, Abidemi K. Adeniji, Fernando Dangond, and Gavin Giovannoni. "Long-term Effects of Cladribine Tablets on MRI Activity Outcomes in Patients with Relapsing–remitting Multiple Sclerosis: The CLARITY Extension Study." Therapeutic Advances in Neurological Disorders 11 (2018): 1756285617753365. https://doi.org/10.1177/1756285617753365.

MLA (9th ed.) Citation

Comi, Giancarlo, et al. "Long-term Effects of Cladribine Tablets on MRI Activity Outcomes in Patients with Relapsing–remitting Multiple Sclerosis: The CLARITY Extension Study." Therapeutic Advances in Neurological Disorders, vol. 11, 2018, p. 1756285617753365, https://doi.org/10.1177/1756285617753365.